Patents by Inventor Glen E. KELLOGG

Glen E. KELLOGG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Polysubstituted pyrroles having microtubule-disrupting, cytotoxic and antitumor activities and methods of use thereof
    Patent number: 9944597
    Abstract: The present invention provides polysubstituted pyrrole compounds, pharmaceutically effective salts, prodrugs, solvates and hydrates thereof, having antimitotic, antiproliferative and cytotoxic activity, activity against cells expressing the drug efflux protein, P-glycoprotein, or cells expressing the ?-III isotype of tubulin and antitumor activity. Also provided are methods of utilizing these compounds for inhibiting the proliferation of cancer cells as well as their medical use, in particular for treating cancer, including drug resistant cancer.
    Type: Grant
    Filed: September 16, 2014
    Date of Patent: April 17, 2018
    Assignees: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM, VIRGINIA COMMONWEALTH UNIVERSITY, UNIVERSITY OF RICHMOND
    Inventors: Glen E. Kellogg, Chenxiao Da, Ashutosh Tripathi, John T. Gupton, Nakul Telang, James A. Sikorski, Susan L. Mooberry, Cristina Rohena
  • POLYSUBSTITUTED PYRROLES HAVING MICROTUBULE-DISRUPTING, CYTOTOXIC AND ANTITUMOR ACTIVITIES AND METHODS OF USE THEREOF
    Publication number: 20160297757
    Abstract: The present invention provides polysubstituted pyrrole compounds, pharmaceutically effective salts, prodrugs, solvates and hydrates thereof, having antimitotic, antiproliferative and cytotoxic activity, activity against cells expressing the drug efflux protein, P-glycoprotein, or cells expressing the ?-III isotype of tubulin and antitumor activity. Also provided are methods of utilizing these compounds for inhibiting the proliferation of cancer cells as well as their medical use, in particular for treating cancer, including drug resistant cancer.
    Type: Application
    Filed: September 16, 2014
    Publication date: October 13, 2016
    Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SY STEM
    Inventors: Glen E. KELLOGG, Chenxiao DA, Ashutosh TRIPATHI, John T. GUPTON, Nankul TELANG, James A. SIKORSKI, Susan L. MOOBERRY, Cristina ROHENA